No Photo Available

Last Update

2016-12-16T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Peter Mueller?

Dr. Peter R. Mueller

President of Research and Development and CSO

Axcella Health Inc

Direct Phone: (508) ***-****       

Email: p***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Axcella Health Inc

840 Memorial Drive

Cambridge, Massachusetts 02139

United States

Company Description

Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular ... more

Find other employees at this company (39)

Background Information

Employment History

President of Research and Development and CSO

Pronutria Biosciences Inc

AMAR

Chief Scientific Officer and Executive Vice President of Global Research and Development

Vertex Pharmaceuticals Incorporated

Senior Vice President, Research and Development

Boehringer Ingelheim Corporation

President

R&D Companies

President

Epicenter Consulting LLC

Chief Operating Officer

Amarillo Biosciences , Inc.

Vice President, Global Marketing and Medical Information and Technology

Aventis SA

Director of Global Commercial Development

Merrell Dow

Affiliations

Advisory Board Member
USA India Chamber of commerce

Board Member
Inhibikase Therapeutics Inc

Board Member
Gesellschaft Deutscher Chemiker

Advisory Board Member
Phacilitate Limited

Scientific Advisory Board Member
Keystone Symposia

Advisory Board Member
Biosensor Forum

Delegate
GDS International Ltd

Faculty Member
Albert Einstein University of Ulm , Germany

Member
American Association for the Advancement of Science

Member
Royal Society of Chemistry

Member
The RNA Society

Member of Council On Economic Competitiveness and Technology for the State of Connecticut
Govenor Roland

Education

MBA

Babson

Ph.D.

Pharmacology

University of Mainz

Ph.D. degree

pharmaceuticals

University of Mainz , Germany

PhD

Chemistry

Albert Einstein University of Ulm , Germany

undergraduate degree

Albert Einstein University of Ulm , Germany

Web References (131 Total References)


Peter Mueller, ...

www.axcellahealth.com [cached]

Peter Mueller, PhD President of R&D and Chief Scientific Officer


Peter Mueller, PhD | Axcella Health, Inc

www.axcellahealth.com [cached]

Peter Mueller, PhD

President of R&D and Chief Scientific Officer
Prior to his time at Axcella, Dr. Peter Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals. At Vertex, he provided strategic oversight for Vertex's worldwide drug discovery and development programs. He was responsible for the build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain, as well as Clinical and Non-Clinical Development, Regulatory and Medical Affairs and Patient Safety. Key areas of Vertex's R&D have been hepatitis C (HepC), cystic fibrosis (CF), Immune Mediated Intestinal Diseases (IMID), cancer and neurological diseases. His leadership led to the successful approval and launch of two breakthrough drugs, INCIVEK (HepC) in 2011, and KALYDECO (CF) in 2012, as well as a, NDA and MAA for Orkambi (CF) and numerous sNDA submissions for KALYDECO (CF) and several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA). Both Breakthrough Therapies got awarded the prestigious Prix Galien award (U.S., Telaprevir) and its European counterpart the Galenus Preis (Kalydeco). Prior to his time at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc., where he was responsible for research in North America and the development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He played a key role in the development of Spiriva, Combivent and Atrovent. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim (BI), starting there in 1984, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University. Special Fields of studies are Synthetic Organic Chemistry, Computational Chemistry (Cheminformatics and Bioinformatics), RNA-Biophysics, Atherosclerosis Research, IMID (Immune Mediated Inflammatory Diseases), Neurodegenerative Diseases, Infection, Oncology, Gene/ Epigenetic Technology and Management Strategies. He is a Board member of various scientific and political societies, such as the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (U.K.); U.S.-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, IRI, RNA-Society, ASAP, AAAS (USA), Inhibikase, Visterra and Kaleido. He has also supported the Harvard Accelerator Fund, the Scientific Advisory Board for Keystone Conferences, and the Governor Roland's Council on Economic Competitiveness and Technology for the State of Connecticut (USA).


Peter Mueller, ...

www.axcellahealth.com [cached]

Peter Mueller, PhD Chief Scientific Officer


Biotech365, Auteur à Biotech 365

biotech-365.com [cached]

Axcella also announced that Peter Mueller, Ph.D., has resigned from his current role as President of R&D and Chief Scientific Officer, to focus on The Mueller Health Foundation, an organization he created that is dedicated to the eradication of global, lethal infectious diseases, with a main focus on tuberculosis.

"During the past two years, Peter has made substantial contributions especially in establishing firm scientific foundations and building a


USA India Chamber of commerce - Delivering Affordable Innovation through Global Partnerships

www.usaindiachamber.org [cached]

Dr. Peter Mueller President R&D and CSO

Similar Profiles

Other People with this Name

Other people with the name Mueller

Chante Mueller
Spark New Zealand

Tanja Mueller
Alpha Translations Canada Inc

Dominik Mueller
SoftwareONE AG

Luke Mueller
Cushman & Wakefield Inc

Chris Mueller
Stonecutters Inc

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory